Alba A Brandes1, Marco Bartolotti1, Alicia Tosoni1, Rosalba Poggi1, Stefania Bartolini1, Alexandro Paccapelo1, Antonella Bacci2, Claudio Ghimenton3, Annalisa Pession4, Carlo Bortolotti5, Mino Zucchelli5, Renato Galzio6, Andrea Talacchi7, Lorenzo Volpin8, Gianluca Marucci4, Dario de Biase4, Stefano Pizzolitto9, Daniela Danieli10, Mario Ermani11, Enrico Franceschi1. 1. Department of Medical Oncology, Bellaria Hospital, Azienda USL - IRCCS Institute of Neurological Sciences, Bologna, Italy. 2. Department of Neuroradiology, Bellaria Hospital, Azienda USL - IRCCS Institute of Neurological Sciences, Bologna, Italy. 3. Department of Pathology, Verona Hospital, Verona, Italy. 4. Department of Biomedical & NeuroMotor Sciences (DiBiNeM), University of Bologna, Section of Pathology, M. Malpighi, Bellaria Hospital, Bologna, Italy. 5. Department of Neurosurgery, Bellaria Hospital, Azienda USL - IRCCS Institute of Neurological Sciences, Bologna, Italy. 6. Department of Health Sciences, University of L'Aquila, L'Aquila, Italy. 7. Section of Neurosurgery, Department of Neurological, Neuropsychological, Morphological & Movement Sciences, University of Verona, University Hospital, Verona, Italy. 8. Department of Neuroscience & Neurosurgery, San Bortolo Hospital, Vicenza, Italy. 9. Department of Pathology, Santa Maria della Misericordia Hospital, Udine, Italy. 10. Department of Pathology, San Bortolo Hospital, Vicenza, Italy. 11. Department of Neurosciences, Statistic & Informatic Unit, Azienda Ospedale-Università, Padova, Italy.
Abstract
BACKGROUND: The most appropriate management of recurrent glioblastoma is still controversial. In particular, the role of surgery at recurrence remains uncertain. PATIENTS & METHODS: From our Institutional data warehouse we analyzed 270 consecutive patients who received second surgery for recurrent glioblastoma, to assess survival after second surgery, and to evaluate prognostic factors. RESULTS: Complete resection was found in 128 (47.4%) and partial resection in 142 patients (52.6%). Median survival from second surgery was 11.4 months (95% CI: 10.0-12.7). Multivariate analysis showed that age (p = 0.001), MGMT methylation (p = 0.021) and extent of surgery (p < 0.001) are associated with better survival. CONCLUSION: A complete resection should be the goal for second resection and younger age and MGMT methylation status might be considered in the selection of patients.
BACKGROUND: The most appropriate management of recurrent glioblastoma is still controversial. In particular, the role of surgery at recurrence remains uncertain. PATIENTS & METHODS: From our Institutional data warehouse we analyzed 270 consecutive patients who received second surgery for recurrent glioblastoma, to assess survival after second surgery, and to evaluate prognostic factors. RESULTS: Complete resection was found in 128 (47.4%) and partial resection in 142 patients (52.6%). Median survival from second surgery was 11.4 months (95% CI: 10.0-12.7). Multivariate analysis showed that age (p = 0.001), MGMT methylation (p = 0.021) and extent of surgery (p < 0.001) are associated with better survival. CONCLUSION: A complete resection should be the goal for second resection and younger age and MGMT methylation status might be considered in the selection of patients.
Authors: Dong Geon Kim; Kang Ho Kim; Yun Jee Seo; Heekyoung Yang; Eric G Marcusson; Eunju Son; Kyoungmin Lee; Jason K Sa; Hye Won Lee; Do-Hyun Nam Journal: Oncotarget Date: 2016-05-17
Authors: Dominic J Gessler; Elizabeth C Neil; Rena Shah; Joseph Levine; James Shanks; Christopher Wilke; Margaret Reynolds; Shunqing Zhang; Can Özütemiz; Mehmet Gencturk; Mark Folkertsma; W Robert Bell; Liam Chen; Clara Ferreira; Kathryn Dusenbery; Clark C Chen Journal: Neurooncol Adv Date: 2021-12-27
Authors: P M Brennan; R Borchert; C Coulter; G R Critchley; B Hall; D Holliman; I Phang; S J Jefferies; S Keni; L Lee; I Liaquat; H J Marcus; S Thomson; L Thorne; M Vintu; A N Wiggins; M D Jenkinson; S Erridge Journal: J Neurooncol Date: 2021-03-31 Impact factor: 4.130